Lactobacillus acidophilus L-92
What does the research say about Lactobacillus acidophilus L-92?
14 health outcomes synthesisedLactobacillus acidophilus L-92 has been studied across 14 health outcomes, with the strongest evidence supporting its role in reducing atopic dermatitis severity. Six studies, including a systematic review and meta-analysis, found moderate beneficial effects in children and adults. One outcome specified an effective dose of 20 mg/day, though most studies did not report precise dosing.
Strongest evidence
The most robust research on L. acidophilus L-92 focuses on atopic dermatitis. Three outcomes — Reduced Atopic Dermatitis Severity (high evidence, 6 studies, moderate effect), Improved Atopic Dermatitis Severity (moderate evidence, 4 studies, moderate effect, dose 20 mg/day), and Improved Atopic Dermatitis Symptoms (moderate evidence, 4 studies, mixed effect) — all report beneficial effects across children and adults. For inflammation, moderate evidence from 9 studies shows a small effect, but only one study reached statistical significance and most trials assessed general probiotics rather than L-92 specifically.
Mixed or weaker evidence
Several outcomes have low evidence strength due to reliance on review articles, lack of primary trials, or small sample sizes. These include Improved Immune Function (12 studies, all beneficial but small effect, only one RCT directly testing L-92), Reduced Allergic Symptoms (11 reviews, moderate effect), Reduced Severity of Allergic Rhinitis Symptoms (10 reviews, moderate effect), Improved Gut Microbiota Balance (6 reviews, mixed effect), and Improved Gut Health (5 animal studies, mixed effect). For these, the direction of effect is consistently positive, but statistical significance is rare and causal attribution to L-92 is uncertain.
Effective dose patterns
Only one outcome — Improved Atopic Dermatitis Severity — reported a specific effective dose: 20 mg/day of L-92 or a heat-killed dried preparation daily. No other outcomes provided consistent dose ranges, limiting the ability to generalize dosing recommendations.
Population insights
Most human studies focused on children and adults with atopic dermatitis, particularly in Japanese populations. For inflammation, studied groups included individuals with type 2 diabetes, underweight individuals, older adults with sarcopenia or obesity, and athletes. Evidence for gut health came exclusively from animal studies (livestock and pets).
Notable caveats
A major caveat across all syntheses is the potential for publication bias — null-result studies are less likely to be published or indexed. Additionally, many studies did not reach statistical significance, and the evidence base often consists of review articles rather than primary clinical trials. Only a few outcomes specified dosing or form, and most studies lacked consistent reporting of duration, dose, and population characteristics.
Frequently asked
What is Lactobacillus acidophilus L-92 good for according to research?
Research suggests L. acidophilus L-92 is most consistently beneficial for reducing atopic dermatitis severity, with high evidence from 6 studies showing moderate effects in children and adults. Moderate evidence also supports improvements in inflammation (9 studies, small effect) and allergic symptoms, though many findings are based on reviews rather than direct trials.What dose of Lactobacillus acidophilus L-92 is typically used in studies?
Only one outcome — improved atopic dermatitis severity — specified a dose: 20 mg/day of L-92 or a heat-killed dried preparation daily. Most other studies did not report a precise dose or form, making it difficult to determine an effective dose range across different health outcomes.Who benefits most from Lactobacillus acidophilus L-92?
The strongest evidence points to children and adults with atopic dermatitis, particularly in Japanese populations. Studies on inflammation included diverse groups such as individuals with type 2 diabetes, older adults with sarcopenia or obesity, and athletes, but effects were small and often not statistically significant.Are there caveats or limitations in the research on Lactobacillus acidophilus L-92?
Yes. Across all outcomes, publication bias is a concern — null results are less likely to be published. Many studies are reviews or meta-analyses of general probiotics, not direct trials of L-92, so causation cannot be attributed to this specific strain. Additionally, most studies did not reach statistical significance, and dosing and study durations were inconsistently reported.Does Lactobacillus acidophilus L-92 help with atopic dermatitis?
Yes, this is the most researched area. High evidence from 6 studies shows moderate beneficial effects on reducing atopic dermatitis severity, and moderate evidence from 4 studies shows benefits for improving severity, with a specific dose of 20 mg/day reported. Four additional studies on atopic dermatitis symptoms also reported beneficial effects, primarily in Japanese populations.
- High evidenceReduced Atopic Dermatitis Severity
- Moderate evidenceReduced Inflammation
- Moderate evidenceImproved Atopic Dermatitis Severity
- Moderate evidenceImproved Atopic Dermatitis Symptoms
- Low evidenceImproved Immune Function
- Low evidenceReduced Allergic Symptoms
- Low evidenceReduced Severity of Allergic Rhinitis Symptoms
- Low evidenceImproved Gut Microbiota Balance
- Low evidenceImproved Gut Health
- Low evidenceImproved Immune Modulation